AI Engines For more Details: Perplexity Kagi Labs You
Antipsychotic Effects: Tiapride is classified as an atypical antipsychotic medication. It is used to manage symptoms of psychiatric disorders such as schizophrenia, psychotic disorders, and other conditions characterized by hallucinations, delusions, disorganized thinking, and agitation.
Treatment of Tourette Syndrome: Tiapride is commonly prescribed off-label for the treatment of Tourette syndrome, a neurological disorder characterized by repetitive, involuntary movements and vocalizations known as tics. Tiapride helps reduce the frequency and severity of tics and may improve overall functioning in individuals with Tourette syndrome.
Management of Motor Disorders: Tiapride is also used to manage various motor disorders, including dystonia, a movement disorder characterized by sustained or repetitive muscle contractions that cause abnormal postures or twisting movements. Tiapride helps alleviate muscle spasms, tremors, and involuntary movements associated with dystonia.
Gastrointestinal Disorders: In some cases, tiapride may be prescribed for the treatment of gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome (IBS). It helps alleviate symptoms such as abdominal pain, bloating, and discomfort by modulating gastrointestinal motility and reducing visceral hypersensitivity.
Minimal Sedation: Compared to typical antipsychotic medications, tiapride is known for its minimal sedative effects. It is generally well-tolerated and less likely to cause sedation or cognitive impairment, making it suitable for long-term use in psychiatric and neurological conditions.
Fewer Extrapyramidal Side Effects: Tiapride has a lower risk of causing extrapyramidal side effects such as parkinsonism, akathisia, and tardive dyskinesia compared to typical antipsychotic drugs. This makes it preferable in certain patient populations, especially those who are prone to movement-related side effects.
Adverse Effects: Common side effects associated with tiapride therapy may include drowsiness, dizziness, headache, dry mouth, gastrointestinal disturbances, and weight gain. Rarely, tiapride may cause more serious adverse effects such as neuroleptic malignant syndrome (NMS), a potentially life-threatening condition characterized by fever, muscle rigidity, altered mental status, and autonomic dysfunction.
Cardiovascular Effects: Tiapride may prolong the QT interval on electrocardiogram (ECG), leading to an increased risk of arrhythmias, including torsades de pointes. It should be used with caution in patients with pre-existing cardiovascular conditions or those taking other medications that can prolong the QT interval.
Drug Interactions: Tiapride may interact with other medications, particularly those that affect the central nervous system or have additive effects on QT interval prolongation. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking before starting tiapride therapy.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.8 | 0.8 | |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | 0 |
Allergic Rhinitis (Hay Fever) | 0.4 | 0.4 | |
Allergies | 0.6 | 0.3 | 1 |
Allergy to milk products | 0.6 | 0.3 | 1 |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 1.3 | 0.3 | 3.33 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.5 | -0.25 |
Ankylosing spondylitis | 0.8 | 0.4 | 1 |
Anorexia Nervosa | 0.1 | 0.2 | -1 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 0.1 | 0.2 | -1 |
Atherosclerosis | 0.3 | 0.1 | 2 |
Atrial fibrillation | 0.6 | 0.3 | 1 |
Autism | 1.2 | 0.9 | 0.33 |
Barrett esophagus cancer | 0.3 | 0.2 | 0.5 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.4 | 0.1 | 3 |
Brain Trauma | 0.1 | -0.1 | |
Carcinoma | 0.8 | 0.4 | 1 |
Celiac Disease | 0.7 | 0.4 | 0.75 |
Cerebral Palsy | 0.3 | 0.2 | 0.5 |
Chronic Fatigue Syndrome | 1.1 | 0.8 | 0.38 |
Chronic Kidney Disease | 0.3 | 0.3 | |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1 | |
Chronic Urticaria (Hives) | 0.8 | 0.1 | 7 |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.3 | 1.67 |
Colorectal Cancer | 2 | 2 | |
Constipation | 0.3 | 0.3 | |
Coronary artery disease | 0.1 | 0.1 | |
COVID-19 | 2.4 | 2.1 | 0.14 |
Crohn's Disease | 2.1 | 0.7 | 2 |
cystic fibrosis | 0.5 | 0.1 | 4 |
deep vein thrombosis | 0.5 | 0.3 | 0.67 |
Depression | 1.9 | 1.3 | 0.46 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.2 | 0.8 | -3 |
Endometriosis | 1 | 0.1 | 9 |
Eosinophilic Esophagitis | 0.3 | 0.3 | |
Epilepsy | 0.8 | 0.4 | 1 |
Fibromyalgia | 0.8 | 0.5 | 0.6 |
Functional constipation / chronic idiopathic constipation | 0.9 | 0.2 | 3.5 |
gallstone disease (gsd) | 0.5 | 0.3 | 0.67 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.2 | 0.5 |
Generalized anxiety disorder | 0.7 | 0.1 | 6 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 0.2 | 0.1 | 1 |
Halitosis | 0.3 | 0.2 | 0.5 |
Hashimoto's thyroiditis | 0.2 | 0.1 | 1 |
Hidradenitis Suppurativa | 0.5 | 0.5 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 0.4 | |
hypercholesterolemia (High Cholesterol) | 0.1 | 0 | 0 |
hyperglycemia | 0.2 | 0.3 | -0.5 |
Hyperlipidemia (High Blood Fats) | 0 | 0 | |
hypertension (High Blood Pressure | 0.7 | 0.4 | 0.75 |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 0.4 | -0.4 | |
Inflammatory Bowel Disease | 1.7 | 0.5 | 2.4 |
Insomnia | 0.3 | 0.1 | 2 |
Intelligence | 0.4 | 0.4 | |
Intracranial aneurysms | 0.3 | 0.3 | |
Irritable Bowel Syndrome | 0.8 | 0.6 | 0.33 |
Liver Cirrhosis | 1.1 | 0.6 | 0.83 |
Long COVID | 1.2 | 0.8 | 0.5 |
Lung Cancer | 0.2 | 0.2 | 0 |
ME/CFS with IBS | 0.3 | 0.3 | 0 |
ME/CFS without IBS | 0.4 | 0.4 | 0 |
Metabolic Syndrome | 1.5 | 1.4 | 0.07 |
Mood Disorders | 2.2 | 1.3 | 0.69 |
multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
Multiple Sclerosis | 1.3 | 0.7 | 0.86 |
Multiple system atrophy (MSA) | 0.1 | 0.1 | 0 |
Neuropathy (all types) | 0.3 | 0.2 | 0.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.2 | 1.5 |
Obesity | 1 | 1.5 | -0.5 |
obsessive-compulsive disorder | 1.5 | 0.2 | 6.5 |
Osteoarthritis | 0.9 | 0.1 | 8 |
Osteoporosis | 0.4 | 0.1 | 3 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 0.7 | 0.8 | -0.14 |
Polycystic ovary syndrome | 0.5 | 0.2 | 1.5 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.1 | |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
primary biliary cholangitis | 0.1 | 0.3 | -2 |
Psoriasis | 1 | 0.2 | 4 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 0.5 | 1.6 |
Rosacea | 0.1 | 0.1 | 0 |
Schizophrenia | 0.8 | 0.1 | 7 |
scoliosis | 0.1 | -0.1 | |
Sjögren syndrome | 0.5 | 0.6 | -0.2 |
Sleep Apnea | 0.3 | 0.1 | 2 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
Stress / posttraumatic stress disorder | 0.9 | 0.1 | 8 |
Systemic Lupus Erythematosus | 0.9 | 0.1 | 8 |
Tic Disorder | 0.1 | 0.1 | 0 |
Tourette syndrome | 0 | 0.1 | 0 |
Type 1 Diabetes | 0.4 | 0.3 | 0.33 |
Type 2 Diabetes | 1.4 | 1.7 | -0.21 |
Ulcerative colitis | 1.1 | 0.6 | 0.83 |
Unhealthy Ageing | 1.1 | 0 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.